The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 70 results:
Author Title Type [ Year(Asc)]
Filters: Author is Mantzoros, Christos S  [Clear All Filters]
2019
Anastasilakis, A. D., Polyzos S. A., Makras P., Douni E., & Mantzoros C. S. (2019).  Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. Metabolism. 93, 100-102.
Athyros, V. G., Polyzos S. A., Kountouras J., Katsiki N., Anagnostis P., Doumas M., et al. (2019).  Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.. Curr Vasc Pharmacol.
Perakakis, N., Polyzos S. A., Yazdani A., Sala-Vila A., Kountouras J., Anastasilakis A. D., et al. (2019).  Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study.. Metabolism. 154005.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2019).  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.. Metabolism. 92, 82-97.
Polyzos, S. A., & Mantzoros C. S. (2019).  Obesity: seize the day, fight the fat.. Metabolism. 92, 1-5.
Boutari, C., Polyzos S. A., & Mantzoros C. S. (2019).  Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. Metabolism. 96, vi-xi.
Pilitsi, E., Farr O. M., Polyzos S. A., Perakakis N., Nolen-Doerr E., Papathanasiou A-E., et al. (2019).  Pharmacotherapy of obesity: Available medications and drugs under investigation.. Metabolism. 92, 170-192.
Panagiotou, G., Papakonstantinou E., Vagionas A., Polyzos S. A., & Mantzoros C. S. (2019).  Serum Levels of Activins, Follistatins, and Growth Factors in Neoplasms of the Breast: A Case-Control Study.. J Clin Endocrinol Metab. 104(2), 349-358.
Polyzos, S. A., Perakakis N., Boutari C., Kountouras J., Ghaly W., Anastasilakis A. D., et al. (2019).  Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD.. J Clin Endocrinol Metab.
2018
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Makras P., Perakakis N., Kountouras J., et al. (2018).  Irisin in metabolic diseases.. Endocrine. 59(2), 260-274.
Polyzos, S. A., Cundy T., & Mantzoros C. S. (2018).  Juvenile Paget disease.. Metabolism. 80, 15-26.
Polyzos, S. A., & Mantzoros C. S. (2018).  Outliers of bone metabolic diseases.. Metabolism. 80, 1-4.
Upadhyay, J., Polyzos S. A., Perakakis N., Thakkar B., Paschou S. A., Katsiki N., et al. (2018).  Pharmacotherapy of type 2 diabetes: An update.. Metabolism. 78, 13-42.
Kountouras, J., Polyzos S. A., Doulberis M., Zeglinas C., Artemaki F., Vardaka E., et al. (2018).  Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis.. Metabolism. 87, 18-24.
Goulis, D. G., & Mantzoros C. S. (2018).  Reproductive Endocrinology: Novel Insights into Pathophysiology and Clinical Management.. Metabolism. 86, 1-2.
Polyzos, S. A., & Mantzoros C. S. (2018).  Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead.. Metabolism. 78, A4-A9.
2017
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2017).  Adipose tissue, obesity and non-alcoholic fatty liver disease.. Minerva Endocrinol. 42(2), 92-108.
Anastasilakis, A. D., Koulaxis D., Kefala N., Polyzos S. A., Upadhyay J., Pagkalidou E., et al. (2017).  Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD. Metabolism. 73, 1-8.
Polyzos, S. A., Kountouras J., Mantzoros C. S., Polymerou V., & Katsinelos P. (2017).  Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.. Diabetes Obes Metab. 19(12), 1805-1809.
Polyzos, S. A., & Mantzoros C. S. (2017).  Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications.. Metabolism. 72, A4-A10.
Polyzos, S. A., Bugianesi E., Kountouras J., & Mantzoros C. S. (2017).  Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists.. Metabolism. 66, 64-68.
2016
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Triantafyllou G. Α., & Mantzoros C. S. (2016).  Activin A and follistatin in patients with nonalcoholic fatty liver disease.. Metabolism. 65(10), 1550-8.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2016).  Adipokines in nonalcoholic fatty liver disease.. Metabolism. 65(8), 1062-79.
Polyzos, S. A., & Mantzoros C. S. (2016).  Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review.. Metabolism. 65(9), 1297-306.
Anastasilakis, A. D., Polyzos S. A., Skouvaklidou E. C., Kynigopoulos G., Saridakis Z. G., Apostolou A., et al. (2016).  Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans.. Metabolism. 65(10), 1459-65.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.